Careful follow-up for weight in pediatric patients ages 6 to 12 years who received VYVANSE over 12 months suggests that consistently medicated pediatric patients (i.e., treatment for 7 days per week throughout the year) have a slowing in growth rate, measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and 47.2, respectively)
Indianapolis, IN: Eli Lily and Company
2021;385:1451-1461 FDA Prescribing Information Jardiance | Mounjaro American College of Cardiology Clinical Trial Summaries EMPA-REG OUTCOME | EMPEROR-Reduced Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice
Drugs in context , 12 , 2023-6-1
At what point in the course of selecting migraine treatments ketamine should be considered remains in question
The Benefits of Glutathione for Diabetics While the safety of glutathione supplementation is being evaluated, the potential benefits are worth exploring
